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HeteroresistanceOXA-48–producing Klebsiella pneumoniae isolates often show growth of colonies within inhibition zones in car-
bapenemdiffusion assays. The nature of these colonieswas investigated in a series of clinical isolates of OXA-48–
producing K. pneumoniae obtained in the context of a hospital outbreak, and they were found to be persistent
colonies that reproduced again the same phenotype when they were collected and tested in diffusion assays
again. The frequency of mutations conferring resistance to meropenem (8 μg/mL) was determined for the
same isolates. The average mutation frequency was 5.47·10−6 (range: 2.59·10−8–5.87·10−5), and the analysis
of several resistant mutants showed that all of them had mutations in the ompK36 porin gene. Heteroresistance
was investigated using population analysis profiling. The profiles were compatible with mutation frequency
assays, and all the colonies analyzed were resistant mutants. In OXA-48–producing K. pneumoniae, the growth
of persisters seems to be specific of diffusion assays.ance).
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Carbapenem-resistant enterobacteria and, in particular, carbapenem-
resistant Klebsiella pneumoniae have become an important problem in
hospitals around the world during the last decade (Podschun and
Ullmann, 1998; Schwaber and Carmeli, 2008). In enterobacteria, the
major mechanisms that give rise to carbapenem resistance are the
production of plasmid-encoded carbapenemases and decreased outer
membrane permeability (Nordmann et al., 2012). OXA-48 is a class D β-
lactamase highly active against penicillins andwith lower activity against
carbapenems (Queenan and Bush, 2007). OXA-48–producing
K. pneumoniae isolates usually exhibit low-level resistance to carbapen-
ems with meropenem and imipenemMICs frequently below clinical cut-
off values (Oueslati et al., 2015). In K. pneumoniae, reduced susceptibility
to carbapenemsmay arise also by a decrease in outer membrane perme-
ability because of inactivation or altered expression of porins in strains
producing β-lactamases with at least some hydrolytic activity against
carbapenems. (Jacoby et al., 2004; Tsai et al., 2011; Wang et al., 2009).
High-dosemeropenem-based therapyhas been suggested to be useful
to treat infections by OXA-48–producing K. pneumoniae if meropenem
MICs are ≤4 μg/mL (Lowman and Schleicher, 2015). This is supported byprevious studies that recommended meropenem to treat infections by
KPC-producing K. pneumoniae if meropenem MICs were ≤8 μg/mL
(Tumbarello et al., 2015). In both cases, the choice of carbapenem should
be based on MIC data of the infecting strains, and this is particularly im-
portant because a significant degree of diversity in MIC values has been
described in carbapenemase-producing K. pneumoniae isolates (Loli
et al., 2006; Paño-Pardo et al., 2013; Tenover et al., 2006). Alterations in
outer membrane permeability and carbapenemase genes may account
for at least part of this variability (Loli et al., 2006). In addition, carba-
penem heteroresistance has been described in VIM and KPC-producing
K. pneumoniae isolates (Pournaras et al., 2010; Tato et al., 2010).
Heteroresistance is a phenotypic phenomenon where a certain propor-
tion of cells of a bacterial population exhibit a range of susceptibilities to
a particular antibiotic. Heteroresistancemay be the consequence of either
the selection of bacterial mutants (with hereditary genetic changes) or
the growth of persister cells (when the colonies with a susceptibility
different from that of the original population are subcultured the same
phenotype is reproduced again) (El-Halfawy and Valvano, 2015).
OXA-48–producingK. pneumoniaewerefirst detected in our hospital
in December 2010 and have spread through several hospital units since
then (Paño-Pardo et al., 2013; Pérez-Blanco et al., 2018). Twomajor and
several minor sporadic clones have been identified. The 2 major clones
belong to sequence types ST405 and ST11. In addition to the OXA-48
carbapenemase gene, these 2 clones carry genes for CTX-M-15, OXA-1,solates of OXA-48–producing Klebsiella pneumoniae,
Table 1
OXA-48–producing isolates used in this work. The table indicates for each isolate the ST
and the MICs of meropenem measured by E-test and microdilution, and the MICs of
imipenem and ertapenemmeasured by microdilution.
Isolate ST Meropenem
MIC (μg/mL)
Microdilution
Meropenem
MIC
(μg/mL)
E-test
Imipenem
MIC (μg/mL)
Microdilution
Ertapenem
MIC (μg/mL)
Microdilution
KpO1670 ST405 1 0.75 2 8
KpO3210 ST405 0.5 0.25 2 2
KpO8517 ST405 0.5 0.38 1 4
KpO0568 ST405 0.5 0.38 2 8
KpO1439 ST405 2 0.5 4 16
KpO1562 ST405 8 6 8 128
KpO2009 ST405 1 0.5 4 8
KpO2292a ST405 32 N32 16 N128
KpO2307 ST405 32 N32 8 128
KpO3472 ST405 1 0.75 4 16
KpO6219 ST405 1 0.38 2 4
KpO5334 ST405 1 0.5 2 4
KpO7533 ST11 2 0.75 2 8
KpO0973 ST11 2 1 4 16
KpO5588 ST11 2 0.75 2 16
KpO0235 ST11 0.5 0.38 2 4
KpO2989 ST11 1 0.75 2 8
KpO1606 ST11 1 0.75 4 16
KpO7874 ST11 1 0.75 2 8
KpO4003 ST11 4 0.75 2 16
KpO6540 ST45 1 0.38 2 8
KpO6500 ST147 0.25 0.25 2 2
KpO1015 ST323 1 0.25 4 2
KpO6009b ST846 16 N32 32 64
a Porin mutant: GACACC duplication into the ompK36-coding sequence at nucleotide
position 409 (duplication in L3 loop).
b Porinmutant: IS4 insertion into theompK36-coding sequence at nucleotideposition 85.
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the 2 clones display a broad range of MIC values for carbapenems, in-
cluding susceptible, intermediate, and resistant isolates, according to
clinical breakpoints. Some isolates reproducibly display colony growth
within inhibition zones in disk and gradient-diffusion assays, suggesting
the existence of less susceptible cells within the population. The impor-
tance of accurate MIC determination to guide therapy led us to analyze
in detail this phenomenon.
2. Material and methods
2.1. Bacterial strains and susceptibility testing
Twenty-four OXA-48–producing clinical isolates obtained in our
hospital from April 2010 to April 2013 were included. They were arbi-
trarily selected to represent thewhole range of meropenemMIC values.
The isolates had been typed by multilocus sequence typing (MLST),
Diversilab™ (bioMérieux, Marcy l'Étoile, France), or a clone-specific
PCR assay (López-Camacho et al., 2014a). Antibiotic susceptibility was
initially determined using microdilution MIC testing by panel 44
Microscan® (Siemens, USA) and interpreted according to the EUCAST
guidelines (EUCAST, n.d.). Meropenem, ertapenem, and imipenem
MICs were further analyzed by microdilution (ISO 20776-1 standard),
gradient diffusion (Etests, bioMérieux), and disk diffusion assays
(EUCAST). Pseudomonas aeruginosa ATCC® 27853™and Escherichia coli
ATCC® 25922™ were used as controls.
2.2. Population analysis profile (PAP) curves
Cultureswere grownovernight in Luria Bertani (LB) broth and serially
diluted in saline. One-hundred-microliter aliquots of each dilution were
spread on freshly prepared LB plates containing meropenem in a range
of concentrations from 0.125 to 32 μg/mL. The plates were incubated
overnight at 37 °C, and the colonies grownwere counted. The proportion
of resistant bacteria were calculated by dividing the number of colonies
grown on antibiotic-containing plates by the colony counts from the
same bacterial inoculum plated onto antibiotic-free plates. Results were
represented on a semilogarithmic graph with relative resistant popula-
tion frequencies on the vertical axis and drug concentration on the
horizontal axis.
2.3. Mutation frequencies
Cells from overnight cultures (102–103) were inoculated in 5 mL of
LB broth and grown overnight. Aliquots from serial dilutions were
plated onto LB agar plates with and without antibiotic (rifampicin or
meropenem at 300 μg/mL and 8 μg/mL, respectively). Colony counting
was performed after 24 h. Experiments were done in triplicate from in-
dependent colonies.
2.4. Analysis of outer membrane proteins
Cells from 20-mL overnight cultures grown on LB broth were soni-
cated, and outer membrane proteins were extracted and analyzed by
SDS-PAGE (López-Camacho et al., 2014b).
2.5. Molecular methods
Clones were identified by MLST (Diancourt and Passet, 2005) or by
clone-specific real-time PCR for K. pneumoniae ST11 and ST405
(López-Camacho et al., 2014a). The ompK36 mutants were analyzed
by PCR using the primers K1ompK36-F (5′-GCACAATGAAATA
GCCGACTG-3′) and K1ompK36-R (5′-ATCGAGGCTCCTCTTACCAG-3′)
for the coding sequence and ompK36-Prom-F (5′-CCGCCCAGGAA
TTATCTTAG-3′) and ompK36-Prom-R (5′-GTCGTTGATCTGGGTTTCG-
3′) for the promoter sequence. The ompK36 coding sequence and thePlease cite this article as: López-Camacho E, et al, Meropenem heteroresis
Diagn Microbiol Infect Dis (2018), https://doi.org/10.1016/j.diagmicrobio.promoter region were amplified separately with standard PCR condi-
tions, except for a long extension step (5 min) to allow amplification
of long DNA fragments in mutants carrying insertion elements. The
final products were visualized by agarose gel electrophoresis. PCR am-
plification products were sequenced and compared with the ompK36
sequence of the previously sequenced ST405 isolates KpO3210
(Wesselink et al., 2012) and K. pneumoniae 909957 (Genbank accession
number NZ_AXUL00000000). Screening for OXA-48, SHV, CTX-M, TEM,
and OXA-1 β-lactamase genes was done by PCR (Jones et al., 2009;
Paño-Pardo et al., 2013).3. Results
3.1. Bacterial populations
Twenty-four OXA-48–producing clinical isolates that exhibited
decreased susceptibility to carbapenems and were resistant to most β-
lactams (except the single ST45 isolate, which was susceptible to
cephalosporins) and to amoxicillin/clavulanic acid and piperacillin/taz-
obactam combinationswere studied. In addition to β-lactam resistance,
most of the isolates presented combined resistance to fluoroquinolones,
cotrimoxazole, aminoglycosides (gentamicin and tobramycin), and
fosfomycin. Two isolates were porin-deficient mutants that had high
carbapenem MICs (one ST405 and one ST846, both confirmed by SDS-
PAGE). Twelve isolates belonged to sequence type ST405, 8 to ST11,
and the remaining 4 isolates were characterized as ST45, ST147,
ST323, and ST846 (Table 1). All of them showed growth of colonies
within the meropenem inhibition zones in diffusion assays (either
disks or gradient-strips). These colonies had the same MICs as the
parental isolates and reproduced the colonies-within-zone phenotypes
when retested, indicating they were persister cells.tance in clinical isolates of OXA-48–producing Klebsiella pneumoniae,
2018.09.008
Table 2
Mutations found in the ompK36 porin gene in a set of spontaneous meropenem-resistant
mutants from different ST405 isolates. Numbers in parentheses indicate the nucleotide
positions of the mutations within the ompK36 gene sequence. Negative numbers indicate
positionsupstreamof the ompK36 start codon. Premature stop codonnumbers correspond
to amino acid position of the unprocessed protein sequence.
Isolate Genetic change (nucleotide position)
and codon modification
Genetic lesion at
protein level
KpO8517–1 (−95)::IS1 (3′ → 5′) NE
KpO8517–2 (−95)::IS1 (3′ → 5′) NE
KpO8517–5 (−23)::IS1 (3′ → 5′) NE
KpO0568–5 G → A (375); W125STOP NE
KpO0568–7 ΔAG(271–272); FS NE
KpO1439–6 ΔA(524); FS NE
KpO1439–7 G → A (375); W125STOP NE
KpO1439–8 (−4)::IS1 (3′ → 5′) NE
KpO2009–3 (−22)::IS1 (3′ → 5′) NE
KpO2009–10 (−36)::IS1 (3′ → 5′) NE
KpO2307–1 (409)::(GACACC); D137-T138 duplication OmpK36V
KpO2307–2 (409)::(GACACC); D137-T138 duplication OmpK36V
KpO2307–5 (−31)::IS1 (5′ → 3′) NE
KpO3472–3 (−72)::IS1 (3′ → 5′) NE
KpO3472–4 G → A (375); W125STOP NE
FS = frameshift; NE = not expressed (no protein detected by SDS-PAGE); OmpK36V =
OmpK36 variant.
3E. López-Camacho et al. / Diagnostic Microbiology and Infectious Disease xxx (xxxx) xxx–xxx3.2. Measurement of meropenem-resistance mutation frequencies
Mutation to meropenem resistance was characterized by selecting
mutants able to grow in plates with 8 μg/mL meropenem. Only the 2
porin mutants could grow (as expected from their MICs) in those plates,
although a few resistant colonies were observed in some of the other iso-
lates. The frequency of meropenem-resistant colonies was measured
in vitro for 22 isolates. Under the experimental conditions used, no
meropenem-resistant mutants were obtained from isolates KpO0235
(ST11), KpO6500 (ST147), and KpO1015 (ST323). Excluding these 3
isolates (and the 2 porin mutants), the average mutation frequency to
8 μg/mL meropenem resistance was 5.47·10−6 (median: 2.82·10−7),
with a broad range of frequencies: 2.59·10−8–5.87·10−5. For compari-
son, the frequencies of rifampicin resistance mutations were measured
andwere found to be similar for all the isolates, with an averagemutation
frequency of 2.38·10−8 (median: 1.13·10−8) and a comparatively
narrow range of frequencies: 2.82·10−9–8.08·10−8 (Fig. 1).
3.3. Analysis of the carbapenem resistant mutants
Tenmeropenem-resistant colonies fromeach of 8 ST405 isolates and
3 ST11 isolates were randomly selected, and the ompK36 gene of each
one was analyzed. Out of 110 resistant mutants, in 52, the size of the
ompK36 gene amplification product was the same as the wild-type con-
trol (KpO3210) (Wesselink et al., 2012); in 56 colonies, the amplifica-
tion product was 1 kb larger; and in 2 mutants, the ompK36 gene
could not be amplified. The ompK36 amplicons from 15 randomly
selected meropenem-resistant colonies of 6 ST405 isolates were
sequenced (Table 2). The mutants that had amplicons of the same ap-
parent size as the wild-type strain had nonsilent point mutations or
small insertions in the ompK36 coding sequence. The mutants with
larger amplicons had an IS1 insertion element in the ompK36 promoter
region (Table 2). The outer membrane proteins of the IS1 insertion
mutants and the KpO2307-1 mutant, which had a small DNA duplica-
tion into the ompK36 coding sequence (Table 2), were analyzed by
SDS-PAGE. The OmpK36 porin protein could not be detected in any
insertion mutant (Fig. 2). The OmpK35 porin could not be detected in
KpO3210 or any of the mutant isolates even though no mutations1x10-9
1x10-8
1x10-7
1x10-6
1x10-5
1x10-4
Fig. 1. Frequencies of mutation to meropenem and rifampicin resistance in the OXA-48–
producing clinical isolates shown in Table 1. The line indicates the average value of the
mutation frequencies.
Please cite this article as: López-Camacho E, et al, Meropenem heteroresis
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KpO3210 (ST405).
3.4. Analysis of carbapenem heteroresistance in OXA-48–producing
K. pneumoniae: PAP curves
To study heteroresistance, PAP of selected isolates from the 2 major
clones was done. One isolate from a sporadic clone (ST45) that never
had colonies within the inhibition zones was included. The porin-
deficient OXA-48–producing mutant isolate KpO6009, which belongs
to ST846, was used as a carbapenem-resistant control. This isolate did
not present inhibition zone in diffusion assays. PAP curves show that
colonies of both ST405 and ST11 could be obtained in the presence of
meropenem at concentrations as high as 32 μg/mL (Fig. 3). The porin-
deficient KpO6009 isolate expressed high carbapenem resistance
homogeneously. The frequencies of resistant colonies obtained at differ-
ent meropenem concentrations were determined. The curves vary
slightly among the different isolates, but formeropenem concentrations
≥4 μg/mL, the colony frequencies were within the range of themutation
frequencies obtained at 8 μg/mL, suggesting that they might be
meropenem-resistant mutants (Fig. 3). Six randomly selected coloniesFig. 2. SDS-PAGE analysis of outer membrane fractions obtained from selected
carbapenem-resistant mutants obtained in vitro from several OXA-48–producing
isolates. KpO3210 is the carbapenem-susceptible control. KpO8517-1, KpO8517-5,
KpO2009-3, and KpO2307-5 are carbapenem-resistant IS1 insertion mutants. KpO2307-
1 is a carbapenem-resistant mutant with a 6 nt DNA duplication in the ompK36 gene
that generates a 2–amino acid duplication in the internal L3 loop of the porin.
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Fig. 3. Population analysis profiles of selected OXA-48–producing isolates plated in meropenem. The graphs represent the frequencies of colonies grown on the different meropenem
concentrations relative to the plated viable counts. In all 4 panels, the profile of the meropenem-resistant isolate KpO6009 is included as a reference (gray line). The black lines show
the different isolate profiles: A) KpO1670 (ST405), B) KpO7533 (ST11), C) KpO6540 (ST45, this isolate did not have colonies in the growth inhibition zones), D) KpO5588 (ST11). The
dashed gray line shows the average meropenem-resistance mutation frequency obtained at a meropenem concentration of 8 μg/mL (5.47 × 10−6). Open triangles point to the highest
noninhibitory concentration. Gray triangles point to the lowest concentration exhibiting maximum inhibition. The difference between these 2 concentrations is in all cases ≤4 dilutions
(El-Halfawy and Valvano, 2015).
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further analyzed (4 colonies grown at 4 μg/mL of KpO5588 and 2 colo-
nies of both KpO7533 and KpO1670 grown at 16 μg/mL). Meropenem
Etest assays of these colonies showed that none of them presented inhi-
bition zones (i.e., MICs N32 μg/mL). All 6 colonies were retested again
after 3 daily passages on liquid meropenem-free medium, and none of
them presented inhibition zones, showing that they were stable
meropenem-resistant mutants.
4. Discussion
In the course of the current expansion of OXA-48–producing
K. pneumoniae, a broad range of MIC values for carbapenems has been
observed among different isolates, even within those belonging to the
same ST. Some isolates reproducibly display colonies within the inhibi-
tion zones in disk or gradient diffusion assays, independently of theMIC
valuesmeasured bymicrodilution.We have analyzed the frequency and
the nature of the meropenem-resistant colonies in OXA-48–producing
K. pneumoniae clinical isolates obtained in the context of a hospital
outbreak.
Analysis of the colonies obtained with meropenem concentrations
≥4 μg/mL in PAP experiments showed them to be stable resistant mu-
tants, different to the colonieswithin inhibition zones. Their frequencies
were similar to the meropenem resistance mutation frequencies of the
same isolates determined at ≥8 μg/mL and much lower than the
frequencies of persisters within inhibition zones. PAP of several OXA-
48–producing isolates showed that the distance between the highest
noninhibitory concentration and the lowest concentration exhibitingPlease cite this article as: López-Camacho E, et al, Meropenem heteroresis
Diagn Microbiol Infect Dis (2018), https://doi.org/10.1016/j.diagmicrobio.maximum inhibition was 2- to 3-fold, and if the criteria of El Halfalwy
and Valvano were considered (El-Halfawy and Valvano, 2015), those
isolates should not be defined as heteroresistant. Nevertheless, the
growth of persisters inside inhibition zones in disk and gradient diffu-
sion assays shows that there is indeed a subpopulation of cells which
is different from that selected in high meropenem concentrations. This
apparent conflict suggests that for OXA-48–producing K. pneumoniae,
themethodological differences between PAP assays and diffusion assays
are important. In mutation frequency determination and in PAP assays,
the cells are exposed directly to certain antibiotic concentrations, while
in diffusion assays, the antibiotic concentration builds up gradually as
the antibiotic diffuses from the disks or the strips, and this gradual expo-
sure might have a role in inducing persistence in a fraction of the cell
population. Indeed, gradual increases of antibiotic concentration, as
well as preexposure to low antibiotic concentrations, have been
shown to increase persistence in K. pneumoniae (Li et al., 2018; Ren
et al., 2015). Similarly, in diffusion assays, growth on a solid substrate
in the presence of very low initial antibiotic concentrations could be
related to the persistence phenomenon, perhaps because of a biofilm-
like growth in solid media.
The analysis of several meropenem-resistant mutants showed that
the most common mechanism is by far a deficiency of porin expression
or activity. All the mutants analyzed had somemutation in the ompK36
porin gene, and about half of them had IS1 insertions and no detectable
OmpK36 protein. Interestingly, some of the mutations obtained had
been described before in clinical isolates showing that the mutations
selected in vitro are similar to those selected in vivo. One clinical isolate
(KpO2292) and 1 mutant obtained in vitro (KpO2307-1) had the sametance in clinical isolates of OXA-48–producing Klebsiella pneumoniae,
2018.09.008
5E. López-Camacho et al. / Diagnostic Microbiology and Infectious Disease xxx (xxxx) xxx–xxx6-bp duplication (5′-GACACC-3′) in the ompK36-coding sequence that
generated a duplication of 2 amino acid residues in the L3 loop of the
protein, located in the inner part of the pore and probably having an
effect on the size or the functionality of the channel (Dutzler et al.,
1999). The same mutation had been found in an ertapenem-resistant
K. pneumoniae clinical isolate obtained in Italy (García-Fernández
et al., 2010). Three of the mutants obtained independently from differ-
ent isolates had the W125STOP mutation, which had been described
previously in clinical isolates from the United Kingdom (Doumith
et al., 2009).
In summary, when studying heteroresistance in OXA-48–producing
K. pneumoniae, use of PAP assays and gradient diffusion assays may
result in apparently contradictory, not completely congruent results,
which can be related to the methodological differences between these
2 approaches. Analyses of mutants obtained in mutation frequency
assays and in PAP assays show that porin deficiency is the major mech-
anism involved in MIC increases, and the high mutation frequencies
(between 10−5 and 10−4) measured in some isolates suggest that the
risk of development of carbapenem resistance during therapy should
not be disregarded.
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